Brief: PharmaSGP 9-Month Adj. EBITDA At EUR 13.2 Mln
Nov 16 (Reuters) - PHARMASGP HOLDING SE PSGG.DE :
* 9M GROUP REVENUE (EUR 46.2 MILLION)
* PHARMASGP REPORTING 34% REVENUE GROWTH AND INCREASED
PROFITABILITY IN Q3 2021
* 9-MONTH ADJUSTED EBITDA AT EUR 13.2 MILLION
* EXECUTIVE BOARD CONTINUES TO ASSUME THAT FORECAST FOR 2021
FINANCIAL YEAR WILL BE ACHIEVED
* OUTLOOK 2021: MANAGEMENT BOARD NOW EXPECTS REVENUES OF
BETWEEN
EUR 60 MILLION AND EUR 65 MILLION
Further company coverage: PSGG.DE
(Gdansk Newsroom)
((Gdansk.Newsroom@thomsonreuters.com;))
Recent news on PharmaSGP Holding SE
See all newsBrief: PharmaSGP Holding Outlook FY Revenue EUR 132-138 Million
Brief: PharmaSGP Holding Outlook FY Adjusted EBITDA EUR 37-39 Million
Brief: PharmaSGP Holding Q1 Adjusted EBITDA EUR 9.2 Million
Brief: PharmaSGP Holding Outlook FY Revenue EUR 122-128 Million
Brief: PharmaSGP Holding 9M Adjusted EBITDA EUR 27 Million